Characteristics of the study population.

*<p>Two-tailed Mann-Whitney test; † Mean±SEM (range); ND: Not Documented; ^#Fisher's exact test.</p>‡<p>All patients received Steroids, Cyclosporin, Tacrolimus and/or Mycophenolate Mofetil; one patient received both Basiliximab and anti-thymocyte globulins.</p

Treatment with IVIg is associated with a transient decrease in levels of PFR-MCA hydrolyzing IgG.

<p>IgG was purified from the plasma of patients who received IVIg therapy prior to transplantation (full circles) and from patients who did not received IVIg (empty circles). Plasma had been collected prior to renal transplant (D0) and 3 (M3), 12 (M12) and 24 (M24) months after renal transplant. IgG (66.67 nM) was incubated with PFR-MCA (100 µM), a peptide chromogenic substrate, for 24 hr at 37°C. The amount of hydrolysis was quantified by measuring the fluorescence of the leaving MCA moiety, and is expressed in femtomoles of substrate hydrolyzed per minute per picomoles of IgG. Pooled normal human IgG was used as a control source of IgG. Panel A depicts the raw results as scatter dot plots. Panel B depicts the evolution of the mean ± SEM levels of PFR-MCA-hydrolyzing IgG in the two groups of patients with time (*: P = 0.004). The dotted line represents the hydrolysis of PFR-MCA by normal pooled human IgG (mean of 29 measurements; Coefficient of variation: 0.29). Panel C depicts the levels of PFR-MCA-hydrolyzing IgG in patients treated with anti-thymocyte globulins (ATG, full squares) or not (empty squares), as measured in plasma collected 3 months post-transplantation.</p